Integra LifeSciences Announces 100th Patient Enrolled in AERA® Pediatric Registry

Integra LifeSciences announced today the enrollment of the 100th patient in the AERA® Pediatric Registry, a prospective, multicenter observational registry evaluating the real-world clinical performance of the Acclarent AERA Eustachian Tube Balloon Dilation System in pediatric patients eight or older.

The milestone represents one-third of the registry’s planned enrollment of 300 patients and reflects the continued collaboration of participating investigators, research coordinators and clinical sites across the United States. Launched in July 2025, the registry is designed to generate real-world evidence regarding the use of AERA in children with obstructive Eustachian tube dysfunction, or ETD.

“Reaching the 100-patient milestone reflects meaningful progress in building real-world evidence in pediatric Eustachian tube dysfunction and its treatment,” said Christopher Schutt, M.D., vice president, Operations & Excellence, Office of the Chief Medical Officer, Integra LifeSciences. “We are grateful to the research teams and families whose participation is making this work possible. We are hopeful their contributions will help inform future clinical decision-making and advance understanding of care for children with ETD.”

Read the press release here.